Alexander Joseph Ambinder, M.D., M.P.H.

Headshot of Alexander Joseph Ambinder
  • Assistant Professor of Oncology

Specializes in: Adults (18+ years), Geriatrics (55+ years)


Acute Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndromes (MDS), Myelodysplastic/Myeloproliferative Neoplasms more

Research Interests

Experimental Therapeutics for Acute Leukemias; Measurable Residual Disease more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Google Maps

The Bunting Blaustein Cancer Research Building

1650 Orleans Street
Baltimore, MD 21287
The Bunting Blaustein Cancer Research Building - Google Maps


Dr. Alexander J. Ambinder is an instructor of medicine at the Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins. 

Dr. Ambinder has expertise in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and bone marrow transplantation. 

Dr. Ambinder received his B.A. from Washington University in St. Louis. He earned his M.D. from Emory University School of Medicine and his M.P.H. from Emory University Rollins School of Public Health. He completed the Osler Medical Residency Training Program in internal medicine at Johns Hopkins and subsequently served as an Assistant Chief of Service (Chief Resident). He completed his fellowships in Hematology and Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and also served as a Chief Fellow. 

Dr. Ambinder is a member of the American Society of Hematology and the American Society of Clinical Oncology. 

Dr. Ambinder’s principle research interest is in designing and conducting clinical trials inspired by laboratory insights to improve the management of acute myeloid leukemia and myelodysplastic syndrome. He also has an interest in building large databases that will yield insights that allow for more personalized approaches to the care and treatment of patients with blood cancers. more


  • Assistant Professor of Oncology

Departments / Divisions

Centers & Institutes



  • MD; Emory University School of Medicine (2013)


  • Internal Medicine; Johns Hopkins University School of Medicine (2016)


  • Hematology and Oncology; Johns Hopkins University School of Medicine (2017)
  • Oncology; Johns Hopkins University School of Medicine (2020)

Board Certifications

  • American Board of Internal Medicine (Hematology) (2020)
  • American Board of Internal Medicine (Internal Medicine) (2016)
  • American Board of Internal Medicine (Medical Oncology) (2020)

Research & Publications

Research Summary

Dr. Ambinder’s research focuses on translating laboratory-based discoveries into new strategies to treat AML and MDS. He is working on enhancing the effectiveness of approved therapies by counteracting the protective mechanisms that cancer cells use to reduce their exposure to these agents. By pre-emptively blocking these survival mechanisms, Dr. Ambinder aims to eliminate residual leukemia, thereby increasing the chance of cure. Dr. Ambinder is also interested in developing more sophisticated databases that will allow oncologists to leverage cancer center’s cumulative experiences treating blood cancers to provide more personalized recommendations and prognoses for future patients. 

Selected Publications

View all on PubMed

Ambinder A, Miller J, DeZern A. Autoimmune disease in CMML-the chicken or the egg?. Best Practice & Research Clinical Haematology. 2020 June; 33(2):101136-. doi: 10.1016/j.beha.2019.101136

Ambinder A, Hambley B, Shanbhag S, Merrill S. Ibrutinib‐associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins. American Journal of Hematology. 2019 August; 94(11):-. doi: 10.1002/ajh.25611

Dalton WB, Helmenstine E, Walsh N, Gondek LP, Kelkar DS, Read A, Natrajan R, Christenson ES, Roman B, Das S, Zhao L, Leone RD, Shinn D, Groginski T, Madugundu AK, Patil A, Zabransky DJ, Medford A, Lee J, Cole AJ, Rosen M, Thakar M, Ambinder A, Donaldson J, DeZern AE, Cravero K, Chu D, Madero-Marroquin R, Pandey A, Hurley PJ, Lauring J, Park BH. Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. J Clin Invest. 2019 Aug 8;129(11):4708-4723. doi: 10.1172/JCI125022. PubMed PMID: 31393856; PubMed Central PMCID: PMC6819102

Gavriilaki E, Yuan X, Ye Z, Ambinder AJ, Shanbhag SP, Streiff MB, Kickler TS, Moliterno AR, Sperati CJ, Brodsky RA. Modified Ham test for atypical hemolytic uremic syndrome. Blood. 2015 Jun 4;125(23):3637-46. doi: 10.1182/blood-2015-02-629683. Epub 2015 Apr 10. PubMed PMID: 25862562; PubMed Central PMCID: PMC4784297

Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer. 2013 Apr 15;119(8):1570-7. doi: 10.1002/cncr.27898. Epub 2013 Jan 22. PubMed PMID: 23341329

Activities & Honors


  • Assistant Chief of Service (Longcope Firm), Osler Medical Residency Training Program, Johns Hopkins, 2017
  • Chief Fellow, Sidney Kimmel Comprehensive Cancer Center, Hematology/Oncology Fellowship, 2019 - 2020


  • American Society of Hematology, 2016
  • American Society of Clinical Oncology, 2008
Is this you? Edit Profile
back to top button